Journal
JOURNAL OF IMMUNOTHERAPY
Volume 28, Issue 3, Pages 183-192Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cji.0000162781.78384.95
Keywords
interleukin 2; granulocyte colony-stimulating factor; proteomics; immunotherapy; mass spectrometry; ELISA
Categories
Ask authors/readers for more resources
Proteomics is becoming increasingly important for cancer biotherapy. The development of high-throughput platforms now allows the analysis of multiple proteins from small quantities of material. While these techniques are being used to discover new biomarkers, they are particularly important for assessing complex biologic processes such as immunotherapy for cancer. Recent advances in this field are reviewed, as well as the use of proteomics to assess the effectiveness and toxicities of high-dose IL-2 cancer therapy. Proteomics is becoming useful in assessing cancer biotherapies and in unraveling their mechanisms of action. High-throughput proteomic technologies have now advanced to a stage where they have the potential to become effective discovery tools for biomarkers/predictors of disease, disease recurrence, and response to therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available